Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1313)	11/24/2004 5:05:36 PM
From: rjk01	Respond to of 1386

From the globs Pharmos (Nasdaq:PARS) calmed down yesterday, after Monday's storm. RBC Capital Markets published an explanation about Monday's situation, stating that the results of the company clinical trials were exactly what they should have been - markers for upcoming trials. RBC Capital Markets said signs were encouraging for the future. I therefore reiterate yesterday's comment that the company’s press release was initially misunderstood, and that Pharmos's management should learn from the incident. In any event, RBC Capital Marketsretained its target price of $9 for the share.